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1. Introduction 
Personal data is increasingly collected and used in the context of digitalized services. 
Consequently, the amount of personal data stored in information systems is increasing 
exponentially. Besides the primary purpose, collected personal data is used for so called 
secondary purposes, such as for monitoring the quality of provided services, in the 
development of new services or products and for scientific research. In general, secondary 
use is permitted under certain conditions by the existing privacy legislation, in particular, the 
General Data Protection Regulation (GDPR). Additionally, specific legislation addressing 
secondary use of health data (e.g. in the context of biobanks) has been implemented in 
some countries, including Finland1,2.  
VTT initiated the PreMed project in 2017 with the objective of promoting the development of 
a data-driven precision medicine ecosystem in Finland. In particular, the project aims at 
collecting different kinds of companies together with the common objective of exploiting the 
opportunities provided by health data resources. In the first phase of the project (1.5.2017-
31.10.2018) VTT carried out a series of interviews for better understanding of the 
expectations of companies towards exploitation of data and for identifying the bottlenecks 
and challenges faced today. The results of the interviews and the analysis of the current 
status of data-driven precision medicine landscape were compiled into the PreMed phase 1 
report3.  
For phase 2 industrial partners joined the project so that the current consortium consists of:  
Avaintec, FinBB, Crown CRO, Fazer, Medaffcon, Mediconsult, Novartis, Pfizer, Roche 
Diagnostics and VTT.  The project is co-financed by the project partners and Business 
Finland. The project partners represent different roles of the data-driven precision medicine 
ecosystem as indicated in Figure 1.  
In phase 2 (1.11.2018 - 31.12.2019) the main project activity has been focused in preparing 
a retrospective cohort study on pharmacogenomics (PreMed PGx study). The objective of 
the study is to use data from biobanks and national registries to assess the relevance of 
using genotype data in the context of antithrombotic drug therapy. Besides the scientific 
objective, the biobank study is expected to provide valuable information and experience on 
data access processes and related bottlenecks. Additionally, the project has developed a 
system dynamics model for simulating alternative precision medicine ecosystem 
development scenarios. This report, summarizes the activities and obtained results of phase 
2 of the PreMed project. The third and final phase of the project will be carried out during the 
year 2020.  
                                               
1 Biobank Act, https://www.finlex.fi/fi/laki/kaannokset/2012/en20120688.pdf 
2 Act on the secondary use of health and social data, https://stm.fi/en/secondary-use-of-health-and-
social-data 
3 PreMed, phase 1 report, https://www.vtt.fi/sites/premed/deliverables 
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Figure 1. Data-driven precision medicine ecosystem showing roles of PreMed partners.  
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2. Overview of project activities 
Activities carried out during phase 2 of the project are shown in Figure 2. The ecosystem 
model and its implementation as a simulator was carried out in two parts. The first version 
with limited functionality was developed and completed by July 2019. Subsequently, the 
simulator was enhanced by adding several new features during the rest of the year.  
The PreMed PGx study protocol  was written in the beginning of phase 2 as needed for the 
data applications to biobanks and national registers. The data application process was a 
continuing activity throughout the year. Setting up of the analysis environment and data 
pipeline were carried out in parallel with it. Three project workshops were organized during 
phase 2. The project activities and obtained results are described in more detail in the 
following sections.     
 
 
Figure 2. PreMed project activities during phase 2. 
3. Biobank study - research protocol 
3.1 Introduction 
The PreMed PGx study is a retrospective cohort study using data from biobanks and national 
registers. The scientific content for the research protocol was created by VTT researchers in 
close co-operation with external advisors: Docent Kari Harno, Docent Mika Lehto, Professor 
Mikko Niemi and Docent Maija Wolf. The research protocol has been updated according to 
the comments and requests by the biobanks and register controllers during the data 
application process. A short version of the protocol is presented in the following. 
The study is aimed at pharmacogenomics of antithrombotic drugs, which is one of the areas 
where genome technology is expected to have considerable impact to healthcare and 
pharmaceutical product development already in a short time frame. The objective of the 
retrospective cohort study is to assess based on retrospective data the relevance of 
exploiting the patient's genotype data in the context of antithrombotic drug therapy. The 
related clinical setting is depicted in Figure 3.  
 
11 12 1 2 3 4 5 6 7 8 9 10 11 12
Simulator version 1
Simulator version 2
Study protocol
Data applications
Analysis environment setup
Data pipeline
Project workshops
2018 2019
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Figure 3. Clinical setting related to the biobank study. 
The study is based on genome data collected by biobanks - especially in the framework of 
the FinnGen project - combined with patient record and national register data. The results 
are expected to be beneficial in deciding about adopting pharmacogenomic guidance in 
antithrombotic drug therapy.  
3.2 Clinical background 
Antithrombotic (anticoagulant or antiplatelet) therapies are used in the context of various 
clinical conditions and procedures, including atrial fibrillation (ischemic stroke prevention), 
deep vein thrombosis, pulmonary embolism, artificial heart valves and prevention of recurrent 
stroke or heart attack1. Careful therapy selection and dosing is of high importance since 
insufficient prevention of blood clots may lead to life-threatening conditions such as stroke 
and myocardial infarction. On the other hand, a considerable risk of bleeding is associated 
with antithrombotic therapies. In a recent study, the annual risk of warfarin users for stroke 
and bleeding was observed to be 3.1-9.3% and 2.6-7.5% respectively (Lehto et al. 2017). 
The INR (international normalized ratio) laboratory value and the respective time in 
therapeutic range (TTR) measure was shown to strongly correlate with improved patient 
outcomes.  A severe adverse effect of heparin is heparin-induced thrombocytopenia, for 
which prevalence of 0.1-5% and associated mortality of 20-30% has been reported (Salter et 
al. 2016). 
 
Predicting serious adverse drug reactions (ADRs) is a priority for pharmacogenetic research. 
Substantial amount of effort has been invested in investigating genotype related factors of 
drug therapies and a number of pharmacogenetics guidelines have been compiled2. 
Examples of investigated gene variants potentially affecting the response of antithrombotic 
drugs are listed in Table 1Error! Reference source not found..  
 
                                               
1 NHS Newham Clinical Commissioning Group: http://www.newhamccg.nhs.uk/services/conditions-requiring-
anticoagulant-therapy.htm 
2 CPIC: Clinical Pharmacogenetics Implementation Consortium: http://www.pharmgkb.org/page/cpic 
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Table 1. Antithrombotic drugs and genomic variants to be investigated  
Substance ATC1 
code 
Drug 
consumption  
DDD2/1000 
inhab./day3  
Related gene variants: Single 
Nucleotide Polymorphism (SNP) or 
defect 
Referred studies  
Anticoagulants 
Warfarin B01AA03 14,8 CYP2C9 (rs1799853, rs1057910), 
VKORC1 (rs9923231), CYP4F2 
(rs2108622) 
Monie and 
DeLoughery 2017 
Dabigatran B01AE07 2,07 ABCB1 (rs4148738,rs2032582, 
rs1045642), CES1 (rs2244613, 
rs8192935) 
Tseng et al. 2018 
Rivaroxaban B01AF01 
B01AX06 
4,22 ABCB1 (rs2032582, rs1045642, 
rs2032582) 
Tseng & al. 2018 
Apixaban B01AF02 2,65 ABCB1 (rs4148738, rs1128503, 
rs2032582, rs1045642), ABCG2 
(rs2231142), CYP3A5 (rs776746) 
Tseng & al. 2018 
Edoxaban B01AF03 0,09 ABCB1 (rs1045642), SCLO1B1 
(rs4149056) 
Tseng & al. 2018 
Heparin B01AB01 0,08 IL10 (rs1800896, rs1800871, 
rs1800872) 
Pouplard et al. 2012 
Enoxaparin B01AB05 5,68 ABCB1 (rs1045642) and SLCO1B1 
(rs4149056) 
Vandell et al. 2018 
 
Dalteparin B01AB04 0,75   
Antiplatelets 
Clopidogrel B01AC04 7,79 CYP2C19 (rs4244285, rs4986893), 
CES1 (rs71647871)  
Tornio et al. 2018, 
Neuvonen et al. 
2018, Kubica et al. 
2011 
Ticagrelor B01AC24 0,75 CYP4F2 (rs3093235, rs3093135), 
CYP3A4 (rs35599367) 
Tatarunas et al. 
2017, Holmberg et 
al. 2018 
Acetylsalicylic acid B01AC06 69,15 TXBA2R(rs1131882), ADRA2A 
(rs4311994), PLA2G7 (rs7756935) 
and CDKN2B-AS1(rs10120688) 
Poistula et al. 2011 
 
 
 
Strongest pharmacogenetic (PGx) evidence exists for warfarin, heparin and clopidogrel. For 
example, in the prospective ENGAGE AF-TIMI 48 trial with a subgroup of 4833 warfarin-
treated patients, over-anticoagulation was observed to be correlated with genotype during 
the first 90 days of treatment (Mega et al. 2015). For direct oral anticoagulants - dabigatran, 
rivaroxaban, apixaban and edoxaban - potential genome associations have been identified, 
but evidence is still weak.   
 
The cost-effectiveness of PGx-guided treatments has been evaluated in a number of 
publications (Verbelen et al. 2017). In 4 (of 6) publications PGx-guided clopidogrel treatment 
was considered either cost-efficient or cost-saving. For warfarin, 3 (of 12) publications 
                                               
1 ATC= Anatomical Therapeutic Chemical 
2 DDD=Defined Daily Dose 
3 Drug consumption 2017 (Fimea)  https://www.fimea.fi/web/en/databases_and_registeries/consumption 
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considered PGx-guided treatment cost-efficient or cost-saving. This number was increased 
to 7 (of 12) in the case when genotype information was assumed to be already existing 
without extra cost at the time of prescription. Such situation may increasingly prevail in the 
future as services (e.g. the Genome Centre1 in Finland) for secure management and sharing 
of genome data become available.  
 
Pharmacogenetic tests are largely available by laboratory services. Currently, the use of 
such tests is still low due to lack of related clinical guidelines. There is a need for electronic 
health record systems (EHRs) which are capable to connect with genomic information and to 
provide PGx-related decision support for healthcare professionals (Ji et al. 2016).   
 
3.3 Study objectives  
The overall goal is to investigate the feasibility of using genome data in the context of 
antithrombotic therapy.  
The objectives of the study are:  
1. To gain evidence on the association between gene variants and anticoagulation 
control of warfarin therapy.  Earlier research has already shown associations of 
CYP2C9, VKORC1 and CYP4F2 alleles with the efficacy of warfarin. The objective of 
the present study is to obtain further evidence on these associations in the Finnish 
population, which has not been reported in the earlier studies. 
2. To assess the clinical and economic impact of using genotype data in guiding 
warfarin therapy. The aim is to assess if the knowledge of the genome variants is 
likely to lead to better anticoagulation control and less adverse drug reactions. 
Furthermore, the related economic impact will be estimated.  
3. To explore potential genotype-phenotype associations in the context of 
antithrombotic therapy. In particular, direct oral anticoagulants will be investigated 
as their pharmacogenetic properties are not yet well known and their use is rapidly 
increasing. More detailed studies may be initiated based on the findings. 
4. To assess the current usage of pharmacogenetic information in the context of 
antithrombotic therapy. The aim is to increase overall understanding of the total 
volume and clinical context of using pharmacogenetic tests.    
In addition to the clinical objectives listed above the study seeks to collect experience and 
best practices for carrying out co-operative research activities based on combining clinical 
data resources (including genome data). Thereby, the study is expected to provide useful 
information from the perspective of the national activities in setting up the service operator 
(Findata) for secondary use of data, the genome center and centralized biobank services. 
Especially in the exploratory part the study aims to deploy and develop new methods needed 
in processing and data-driven analysis of high-dimension clinical and genome data.     
3.4 Study design 
The research is conducted as a retrospective cohort study combining genotype data from 
biobanks with data from national registers and patient records.  
                                               
1 Finnish Genome Centre: https://stm.fi/en/artikkeli/-/asset_publisher/genomikeskuksen-perustaminen-etenee-
tyoryhman-arviomuistio-lausunnoille 
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The index date of the study is defined as the date of the patient's first purchase of one of the 
investigated drugs, in the time frame of 1.1.2007 - 30.6.2018. The follow-up period is defined 
as:  
 start: 2 years before the index date 
 end:  6 months after the last purchase of the drug 
The inclusion criteria are:  
 The patient has had at least one of the inclusion diagnoses in the time frame 
1.1.2007 - 30.6.2018 , and 
 The patient has used at least one of the investigated drugs in the time frame 1.1.2007 
- 30.6.2018 (based on the drug purchase register of Kela), and  
 The patient is at least 18 years of age at index date, and  
 Genotype data of the patient is available covering at least the variants: 
CYP2C9/rs1799853, CYP2C9/rs1057910 and VKORC1/rs9923231 
  The exclusion criteria are:  
 Permanent residence in Finland less than 12 months during the follow-up period  
 Purchase of any of the investigated drugs in the time frame 1.1.2005 - 31.12.2006  
 
3.5 Methods  
The study approach related to the objectives expressed in Section 3.3:  
Association between gene variants and anticoagulation control of warfarin therapy 
(objective 1):  
A study setting will be employed where the carriers of CYP2C9, VKORC1 and CYP4F2 
variants are compared with the carriers of the corresponding wild-types. For the analysis a 
grouping to normal, sensitive and highly sensitive patients will be used (Mega et al. 2015). 
Standard statistical methods will be used in the analysis to estimate the association between 
genotypes and phenotypes.  
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The following phenotypes will be investigated:  
 INR (international normalized ratio) laboratory data history will be analysed. The 
following parameters will be used to evaluate the quality of the anticoagulation 
control: (1) INR during first month (time-weighted mean), (2) time to reach therapeutic 
range and (3) time in therapeutic range (TTR) during first three months.  
 Bleeding events defined as outcome diagnoses. ISTH1 criteria will be used in 
identifying major bleeding (Schulman & Kearon 2005).   
 The needed drug dose to maintain anticoagulation at therapeutic level2  
Assessing the clinical and economic impacts of using genotype data in guiding 
warfarin therapy (objective 2): 
An analysis of the INR history and patient encounters will be performed. Assessment will be 
made on the clinical and economical impact of PGx-guided treatment, taking into account:  
 Potentially improved TTR leading to reduction in adverse effects (bleeding, 
myocardial infarction or cerebral infarction) and related cost savings 
 Potentially reduced need for laboratory tests and related cost savings 
Available information on healthcare resource use (HCRU) and associated unit costs will be 
used in the health economic assessment. Based on the availability, the assessed information 
will potentially include the following HCRU units, stratified by patient groups with distinct 
TTR-ranges.  
The grand total for each HCRU type will be evaluated, and the estimates will be scaled to “per 
patient” by dividing the grand total by the number of contributing patients, and to “per patient 
year” by dividing the grand total by the total follow-up time of the contributing patients. 
The potential of the previously reported warfarin dosing algorithms3 (Gage et al. 2008) will be 
assessed. 
Exploring candidate genotype-phenotype associations in the context of 
anticoagulation and antiplatelet therapies (objective 3): 
A multivariate genotype-phenotype association analysis will be carried out based on data-
driven classification methods. The analysis will be separately performed for each 
investigated drug, for which sufficient amount of data is available. Genome variants to be 
included in each analysis are listed in Section 3.6. INR laboratory tests are routinely 
performed only for warfarin users and INR data will only marginally be available for the users 
of other drugs. For all drugs under investigation the outcomes as listed in Section 3.6. will be 
used. Also other relevant phenotype data will be derived from the available data sets for this 
explorative analysis. Possible interactions of identified potentially interactive drugs with the 
antithrombotic drugs under study will be taken into account in the analysis.  
Assessing the current usage of pharmacogenetic information in healthcare (objective 
4):  
                                               
1 International Society on Thrombosis and Haemostasis, https://www.isth.org/ 
2 This can be performed in case warfarin dosing information will be available 
3 CPIC: Clinical Pharmacogenetics Implementation Consortium: http://www.pharmgkb.org/page/cpic 
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The amount of performed pharmacogenenetic tests will be evaluated based on the available 
laboratory data. The laboratory codes to be observed are: B -Varfa-D and  B -Farma-D 
(pharmacogenetic panel).  
3.6 Data resources  
Antithrombotic drugs and genomic variants to be investigated are listed in Table 1 Error! 
Reference source not found.. The objective has been to include all drugs with considerable 
use for antithrombotic drug therapy in Finland. The genome variants have been selected 
based on observed or potential association with the investigated drugs as documented in 
existing literature. The inclusion and outcome diagnoses are listed in Table 2. Additionally 
the study will use laboratory test results (especially INR-values) and information resulting 
from healthcare encounters and hospital visits.       
Table 2 Diagnoses to be used (inclusion criteria and outcomes) 
ICD 10 code Description Needed as 
I48 Atrial Fibrillation inclusion criteria 
I20-I25,  
I65-I66, I67.2, I70 
Vascular disease inclusion criteria 
I26  Pulmonary embolism inclusion criteria and 
outcome 
I63, I64, I65, I66,  
I69.3-I69.8 
Stroke / cerebral infarction or 
atherosclerosis in (pre-)cerebral arteries 
inclusion criteria and 
outcome 
I80 Phlebitis and thrombophlebitis  inclusion criteria 
I81 Portal vein thrombosis inclusion criteria 
I82 Other venous embolism and thrombosis  inclusion criteria 
D50.0, D62, D68.3  
I60-I62, I69.0-I69.2, I85.0 
J94.2 
K22.1, K22.3, K22.6, K25.0, 
K25.2, K25.4, K25.6, K26.0, 
K26.2, K26.4, K26.6, K27.0, 
K27.2, K27.4, K27.6, K28.0, 
K28.2, K28.4, K28.6, K29.0, 
K62.5, K63.1, K63.3, K92.0-
K92.2 
N02 
R04, R31, R58 
S06.2-S06.6, S06.8 
Bleeding events outcome 
D69.6 Heparin-induced thrombocytopenia outcome (for objective 3) 
I24 Other acute ischemic heart diseases outcome 
D68.3 Hemorrhagic disorder due to circulating 
anticoagulants 
outcome 
C00-C97 Neoplastic disorders  potential impact to 
outcome 
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The patient cohort is formed from three parts provided through the biobanks: Helsinki 
Biobank, Auria Biobank and THL Biobank. Each biobank will identify the eligible patients 
based on the inclusion diagnoses and availability of genome data for the subject. The 
biobanks will be responsible for linking  the data for the subject group from the registers 
(THL, Kela, patient records and laboratory systems). The subjects will be from the following 
geographical areas:  
 Helsinki Biobank subjects: Hospital District of Helsinki and Uusimaa, South 
Karelia Social and Health Care District (Eksote), Kymenlaakso Social and Health 
Services (Carea) 
 Auria Biobank subjects: Hospital District of Southwest Finland, Hospital District 
of Vaasa and Satakunta Hospital District. 
 THL Biobank subjects: Finland.  
 
3.7 Sample size 
The number of patients to be available for the study was estimated based on the initial 
enquiries to the biobanks as:   
 
 Warfarin pharmacogenetics investigation (objectives 1-2), total:  2678 patients 
o Helsinki Biobank: 735 patients 
o Auria Biobank: 301 patients 
o THL Biobank: 1642 patients1      
 
 Explorative study on anticoagulants and antiplatelets (objective 3), total:  5924 
patients 
o Helsinki Biobank: 1626 patients2  
o Auria Biobank: 666 patients 
o THL Biobank: 3632 patients3    
 
Prior studies indicate that the risk rate for bleeding complications in warfarin users is 
approximately 5% (Lehto et al. 2017) and the prevalence of CYP2C9/rs1799853 or 
rs1057910 carriers is 35% (Sistonen et al. 2009 and CPIC data4). Assuming alpha level of 
0.05 and power of 0.9, the estimated number of patients (n=2678) for the warfarin 
investigation (objective 1) would enable us to detect an increase in the bleeding risk from 
presumed 5% to 9% (RR=1.8)  for the carriers of  CYP2C9/rs1799853 or rs1057910.  
 
In earlier studies (Higashi et al. 2002, Aithal et al. 1999) increased bleeding risk of 2.4-3.7 
has been observed for CYP2C9/rs1799853 or rs1057910 carriers.      
3.8 Limitations of the study 
This study is based on real-world evidence data reflecting the actual data available from the 
selected patient cohort. The data collected for this study is existing standard of care data and 
may therefore be partially non-standardized and incomplete. Missing values are thus also 
                                               
1 Estimated as proportion of warfarin users from the total number of 4734 patients with atrial fibrillation, pulmonary 
embolism or ischemic stroke. 
2 Estimated number of all anticoagulant/antiplatelet users based on the number of 735 patients with warfarin. 
3  Estimated as proportion of anticoagulant/antiplatelet users from of 4734 patients with atrial fibrillation, 
pulmonary embolism or ischemic stroke. 
4 CPIC: Clinical Pharmacogenetics Implementation Consortium: http://www.pharmgkb.org/page/cpic 
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expected. In particular, this limitation applies to THL registry data on primary care (Avohilmo 
register), which has only been collected since 2011. It is known that the Avohilmo register 
contents is not complete and uniform across Finland. Missing THL registry data can be partly 
compensated by patient record data from patient records for the subjects of Helsinki Biobank 
and Auria Biobank. After the data has been collected the differences between the data sets 
(Helsinki Biobank, Auria Biobank, THL Biobank) will be assessed and taken into account as 
appropriate. 
For some of the drugs listed in Table 1 the amount of subjects will be low and will not be 
sufficient for statistically significant conclusions. This is certainly the case for the direct oral 
anticoagulants which have been in the markets only for a short time. With the resources and 
timelines of the project, it has not been possible to increase the number of subjects. However, 
the exploratory part of the project addressing these drugs is still expected to provide valuable 
outputs indicating relevant topics for further studies. 
The drug purchase register of Kela does not include information for over-the-counter drugs. 
For such drugs, information may be available in the patient record, but will not be complete.   
3.9 Significance of results  
The results of the project are expected to contribute to improved outcomes of antithrombotic 
drug therapies. 
Concerning warfarin, the study is expected to provide evidence between the association of 
gene variants, individual responses to drugs and the control of anticoagulation therapy in the 
Finnish population, which has not been covered by existing research. The study will also 
assess aspects related to the clinical feasibility and benefits on the use of genome data in 
the context of warfarin therapy. Thereby, the results of the study may contribute to new care 
recommendations incorporating genome-dependent factors. Such recommendations are 
expected to improve therapy outcomes, for example in avoiding adverse effects of warfarin 
therapy.    
Concerning antithrombotic drugs in general, the study will identify candidate genotype 
associations. Especially interesting drugs are direct oral anticoagulants as their use is rapidly 
increasing and their pharmacogenetic characteristics are not sufficiently well known yet. This 
study may identify interesting candidate associations, which may need to be further 
investigated in follow-on studies. Such research is needed in order to properly understand 
the genetic associations of the drugs in the Finnish population and to create new clinical 
guidelines to improve therapy outcomes.   
As a whole, the study aims to provide a generic model and best practices for genome data 
studies exploiting high-dimensional individual-level data mining and modelling approaches. 
This way the results are intended to be applicable to a wide range of clinical domains and 
therapies. The study is expected also to provide useful information from the perspective of 
the national activities in setting up the Findata service operator for secondary use of data, the 
genome center and centralized biobank services.  
4. Biobank study - data collection 
As the research protocol was completed the data collection proceeded by writing data 
applications for the three biobanks (Helsinki Biobank, Auria Biobank and THL Biobank), Kela 
and THL registry authority. The THL registry application covers the laboratory databases and 
therefore separate applications to laboratory data register controllers is not needed.  
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4.1 Data collection approach  
The data collection approach of the PreMed study is illustrated in Figure 4. After acceptance 
of the data application and signing of the Material Transfer Agreement (MTA) each biobank 
composes their target group (list of person ID's) matching the inclusion criteria concerning 
diagnosis, age and availability of genotype data.  In composing the initial target group Auria 
Biobank and Helsinki Biobank use diagnosis data from the patient register via corresponding 
datalakes. THL biobank composes the initial target group based on Finriski and Health 
2000/2011 cohort study data. A joint method for pseudonymization and the related secret key 
was agreed between the biobanks in order to enable detection of overlapping patients from 
pseudonymized data at a later stage.  The initial target groups (person ID lists) are then 
provided by each biobank to the THL (registry authority), Kela and the controllers (or 
processors) of the laboratory data registers. Each of them extracts data for the target groups 
as defined in the study protocol and returns data back to the biobank. The final target groups 
are formed by applying the drug purchase data of Kela to the initial target groups. 
Pseudonymized data sets are composed by each biobank and delivered to VTT.  
 
 Figure 4. Approach for data collection 
 
 
4.2 Data applications  
The data application forms and related processes vary between the data controllers. At the 
time of PreMed data application preparation Helsinki Biobank and Auria Biobank were using 
the same online service (Proma), but with different form contents and required annexes. THL 
Biobank was using the REMS online application system.  The application for Kela needed to 
be filled in a pdf form and submitted by email. THL registry authority's process followed the 
same pattern but with an application form in RTF format.   
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The timeline of the data application process is shown in Figure 5. For Helsinki Biobank a 
review and recommendation by the HUS ethical committee needed to be obtained before the 
actual biobank application could be submitted. For the other data providers, separate ethical 
review was optional. The positive recommendation of the HUS ethical committee was 
annexed to the Helsinki Biobank, THL Biobank, Kela and THL registry applications which 
were submitted after the ethical review was completed.  
As can be shown in Figure 5, the decisions for the applications were mostly received within  
the time frame initially estimated: Helsinki Biobank and THL biobank in 1,5 months, Auria 
Biobank in one month and Kela in 3 months. All processes involved some adjustment or 
clarification to the application before final positive decision was given. No adjustment or 
clarification was requested by THL registry authority, but the application evaluation process 
took 8 months.  The reason for the excess time was explained to be caused by congestion 
due to high number of applications and lack of sufficient resources for application processing.   
The process of compiling of MTA agreements with the biobanks took time between 1,5 - 3,5 
months after acceptance of the application. First data delivery was provided by Auria 
Biobank in October in line with the MTA.  In the case of Helsinki Biobank, THL Biobank and 
Kela data delivery was bound to the acceptance of the THL registry data application and 
therefore delayed.  
 
 
Figure 5. Data application process timeline    
 
4.3 Discussion on data application process 
In order to achieve a sufficient amount of patients, the PreMed study needed data from three 
biobanks. At the time of PreMed study preparation there were no joint biobank services 
available. Most biobank projects so far have been using data and/or samples from one 
biobank only - there was not much prior experience about joint biobank projects.  
From the biobank customer perspective, there is a need for harmonizing procedures among 
the biobanks, e.g. in methods for national registries linkage, pseudonymization methods, 
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data delivery mechanisms and data formats. Joint biobank services would be highly 
appreciated covering at least: data availability requests, biobank applications and 
agreements. Such services are now gradually evolving. The Fingenious service1 of FinBB 
provides now a single channel for finding out the availability of biobank samples and 
submitting requests for feasibility studies and data/sample access. The services cover six 
Finnish hospital biobanks and partly also the THL Biobank.  During year 2020 the new data 
permit authority (Findata) starts to provide centralized services for secondary use of health 
and social services register data. The co-operation model between biobanks and Findata is 
still under discussion.  
5. Biobank study - data analysis environment 
5.1 Research server 
Data analysis activities are carried out at the research server, which also keeps the original 
data sets as well as the results of data analyses. The research server resides in a secured 
physical location at VTT and can be accessed only from computers connected to VTT's 
intranet. The data is stored in encrypted disks and the server access is only allowed for the 
study group of VTT's researchers listed in this research plan. The server has 160GB RAM, 
20 cpu cores, Nvidia Quadro K5000 GPU and 2TB of storage. 
5.2 Data pipeline 
The pipeline for producing analysis results from source data is shown in Figure 6. Data is 
delivered to VTT via the biobanks. In all cases the data is delivered in pseudonymized form 
(see Section 4.1) over a secure delivery channel, such as secure email or SFTP and 
organized in data table form, such as CSV. The incoming files are manually loaded in the 
staging area - a specific folder of the research server.  
A set of R scripts has been programmed for making any needed transformations for the data 
and loading it to the research database (PostgreSQL). By executing the scripts the research 
database can be re-created from the received data files always when needed.   
The research database schema divides into 23 tables collecting data from the various 
sources. There is one outcome and one event table for the users of each of the 11 
investigated drugs. Additionally, there is one outcome table containing key outcomes and 
background data for all patients. 
Based on the drug purchase data the patient's outcome data (diagnoses, laboratory results) 
is inserted to one or several drug-specific outcome tables. All events (outpatient visits, 
hospital visits) are inserted to one events table. The outcome tables are used especially in 
the analysis of the genotype-phenotype associations while the events tables enable the 
analysis of care paths and related healthcare costs. The summary table enables baseline 
analysis of the characteristics of the whole cohort. Events table is used to collect information 
needed in estimating healthcare costs.   
Data analysis and visualisation is based on data retrieved from the research database. For 
example, the following analysis and visualisation scripts will included:  
                                               
1 https://finbb.fi/access-finbb-biobanks-fingenious/ 
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 verification of data by comparing to existing statistics (e.g. drug purchase statistics, 
genotype frequencies, etc.) 
 statistical analysis of association between gene variants and anticoagulation control 
of warfarin therapy as measured by the outcome diagnoses and laboratory results 
(INR) 
 evaluation of healthcare costs based on the events (encounters) data for assessing 
the clinical and economic impacts 
 statistical analysis of candidate genotype-phenotype associations in the context of 
anticoagulation and antiplatelet therapies  
 
 
Figure 6. Data pipeline 
As a preparation for the exploratory data analysis the Facets visual data exploration tool1 has 
been prepared for the analysis environment. The original version was supporting only Google 
Chrome web browser but the standalone PreMed implementation is now tested and 
functional both with Firefox and Google Chrome. The Facets tool includes two applications 
“Facets Overview” and “Facets Dive”. The first tool calculates the basic statistics from every 
variable of the given dataset and creates a web application for easy investigation of data. 
The Dive tool creates a web application which enables to study multiple variables at the 
same time by grouping them interactively according to the user selections. Maximum of six 
variables can be compared at a time.  
6. Ecosystem simulation  
6.1 Overview 
The data-driven precision medicine ecosystem is expected to lead to remarkable economic 
benefits through new products and business opportunities. However, considerable public 
investments are needed e.g. to establish the required infrastructure (data/samples, biobank 
                                               
1 https://pair-code.github.io/facets/ 
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processes), to accelerate the R&D of ecosystem companies and to support related academic 
research. For decision-makers an important question is how to support the data-driven 
precision medicine ecosystem growth to achieve maximum benefit for the society. The 
PreMed project is developing a system dynamics (SD) model for simulation of alternative 
development paths of the ecosystem.  Figure 7 shows the high-level ecosystem diagram 
indicating alternative targets for public investments. The primary outcome measure is the 
volume of real world data projects making use of data obtained from biobanks and national 
registers.   
 
Figure 7. High-level ecosystem model showing main stakeholder groups and dependences 
affecting the exploitation of health data.  
 
6.2 System dynamics method 
System dynamics method is a collection of tools to describe and comprehend how different 
parts of a system are interconnected and how they create the behaviour of the whole system. 
Dynamic complexity (Sterman 2000) does not require a large number of stakeholders in the 
system, it is caused by interconnections in the system, for example, nonlinear feedback 
loops and time delays. Dynamic complexity means that the actions and their effects can be 
far away in time and space, and therefore such systems are in some cases challenging to 
fully understand without suitable tools, for example, system dynamics.  
System dynamics is based on the assumption that the structure of the system causes its 
behaviour, and thus, the focus is on modelling the structure of the system, i.e. the feedback 
loops. The structure can be deconstructed into two basic building blocks, 1) positive / 
reinforcing feedback loop (marked by R in the diagrams) and 2) negative / balancing 
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feedback loop (marked by B in the diagrams). The reinforcing feedback loop tries to cause 
exponential growth or exponential decay, depending on the current state of the system and 
the parameters. The balancing feedback loop is a goal seeking behaviour, it tries to drive the 
state of that loop to match the target value. 
When a model is constructed using these two elemental building blocks, it is possible to 
simulate and study how the different parts of the model affect each other. As the behaviour is 
caused by the feedback loops, by studying the strengths of the feedback loops it is possible 
to come to a conclusion which feedback loops are the most important at a given time. 
Usually some feedback loops dominate in the early phase and then the loop dominance 
shifts to some other loops. For example, growing ecosystems often grow exponentially in the 
early phases, the reinforcing feedback loops dominate, and then at some point the growth 
starts to saturate as the loop dominance shifts to a balancing feedback loop. By 
understanding the interplay of the feedback loops, it is possible to design system wide 
strategies in a way that enables the most beneficial behaviour to occur with the least amount 
of resources. 
The benefits of a system dynamics modelling and simulation study consists of the following 
parts: 
 Visualise the system 
 Communicate the understanding how the system works 
 Challenging assumptions 
 Understanding the different effects of different parts of the system on the whole 
system 
 Sensitivity runs to study how the parameter values affect the behaviour 
 Trying different strategies and design strategies that produce desired behaviour 
We are interested in different behaviour modes (Figure 8), that is, what are the growth 
drivers in the system (reinforcing feedback loops) or what prevents the system from growing 
(balancing feedback loops). 
 
Figure 8: Ecosystem behavioural modes 
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6.3 Simulation model 
 
As outlined in Figure 7 exploitation of health data involves a wide range of companies and 
public organizations forming a complex system. 
The system model consists of eight sectors / subsystems that interact with each other. 
Sectors are: 
 Biobank donors and donor services: Describes the number of persons who have 
given a consent for the use of their health care data and samples as well as the 
processes that lead to the increase of the number of given consents, i.e. biobank 
donors. 
 Biobank samples and data: Describes the amount of samples and data collected 
from the biobank donors as well as the processes how the samples are gathered and 
how the data is generated. 
 Pharmaceutical R&D: Describes the research and development conducted by the 
pharmaceutical companies that is specifically related to health care data. Real world 
evidence (RWE) projects are typical examples of pharmaceutical R&D. The R&D 
actvitiy is measured in number of projects. 
 Academic research: Describes the academic research that is specifically based on 
health care data. Research activity is measured in number of projects. 
 Findata: Describes the Social and Health Data Permit Authority Findata, which is 
starting its operation in the beginning of 2020. Findata is designed to be a gate for the 
secondary use of social and health data, that is, the applications for the use of social 
and health data will be processed by Findata. The operation of Findata will begin 
gradually. Before Findata services all applications have been processed by the 
different data controllers separately. 
 Competence centers / Centers of Excellence (National Cancer Center, Drug 
Development Centre, Neurocenter Finland): Describe the operation of different 
competence centers, respectively National Cancer Center (founded 2019), Drug 
Development Centre (not yet founded), and Neurocenter Finland (not yet 
operational), from the point of view of the studied ecosystem, that is, the  research 
coordination and building connections between academic research and industry.  
 Genome Centre: Describe the operation of National Genome Centre that is under 
development from the point of view of the studied ecosystem. The Genome Centre is 
planned to serve as a one-stop shop in all matters related to genomics and to be a 
population wide genome database. Genome Centre has not yet started its operation.  
 Support services: Describes the services which the pharmaceutical companies 
need in their R&D projects and which they are not able (or willing) to do themselves. 
These services may include different kinds of data analytics, laboratory analyses, 
software development, etc. Support services consists mainly of private sector 
companies, but it also includes the analyses done by research centers and other 
publicly funded organizations. 
The main interest of the model, presented in Figure 9, is to study the interconnections 
between biobank donors, samples and data, and pharmaceutical R&D as well as to study 
how the public investments (green parameters in the model) or lack of them will affect the 
evolvement of the ecosystem. In the model public investments are focused to the following 
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parts of the ecosystem in no particular order: 1) Biobanks, 2) Donor services, 3) Findata, 4) 
Academic research, 5) National Genome Center, 6) Competence centers / Centers of 
excellence, and 7) Support services.  
 
Investments to biobanks refer to additional funding to individual biobanks or FinBB through 
the state budget or through targeted R&D projects (such as Finngen). Such investments are 
targeted to setting up the various biobank processes to build sample and data resources and 
improve access to them.  Donor services are considered as a specific area, where the 
investments are targeted to bring benefits for the biobank donors with the objective of 
increasing the number of donors (given biobank consents). Investments to Findata are 
provided through the state budget and targeted to setting up the basic processes and 
information systems to handle data permit applications, connect data resources and to 
support secure processing of data. Investments to academic research (e.g. via the Academy 
of Finland) refer to public funding of academic research projects based on retrospective data 
resources.  Investments to the competence centers refer to public funding of setting up the 
national centers of excellence (genome, cancer, neuro and pharmaceutical development). 
The National Genome Center is modelled as separate entity due to its intended role in 
maintaining the national genome database. Investments to support services appear as R&D 
funding (e.g. via Business Finland) to SME companies, which provide various services 
needed in exploiting data and sample resources.           
 
Notice that pharmaceutical companies is the only major sector in the model that is not 
receiving public investments, or more accurately, the public investments (e.g. EU-project 
financing)  the pharmaceutical companies may be receiving is included in the R&D budget of 
the companies and thus not explicitly modelled. The R&D activities are considered mainly 
from the point of view of the pharmaceutical companies, as it is at the moment the main 
sector using biobank data and seen as the major sector in the model. However, the model is 
also applicable to other businesses utilizing health data to support their R&D activities. 
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Figure 9: Simplified diagram of the simulation model 
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Analysis of key variables is the model: 
 Effects on Available data resources for secondary use (see Figure 10):  
 We have assumed that the main driver for the pharmaceutical companies to 
conduct data driven research is the amount of health data available to use. 
We have not taken into consideration the possible effects of the number of 
donors relative to available data, or different kind of health data, but 
aggregated the effect of these in the single variable Available data resources 
for secondary use.    
 Available data resources for secondary use is a combination of the following 
data resources: Data and samples in biobanks, Register data, and Availability 
of MyData. Also, the Data integration capability affects the amount of data 
available, as it describes how the different data sources can be combined 
together, and thus affects the amount of data available, as the combined data 
can be seen as an own data source. 
 
 
 
 
Figure 10: Available data resources for secondary use 
 Effects on R&D project proposals (see Figure 11):  
 One of the main focal points of the model is to determine what affects the 
pharmaceutical R&D project starts or the R&D project proposals as the project 
starts is a delayed function of the project proposals. Figure 11 shows the 
variables affecting the R&D project proposals.  
 The main effect comes from the Available data resources for secondary use, 
which has been already discussed earlier. The other variables have lesser 
impact, although, they are still important. R&D budget has a major impact on 
the project proposals in the future if the number of R&D projects increases 
and the budget becomes a limiting factor for the projects. Support service 
availability has only a negative impact if the support services cannot match the 
requirements of the ongoing R&D projects. The effects of Findata come 
through the improved application process  reducing the needed effort  for 
accessing data and are a positive factor for project proposals.  
 
 
 
Figure 11: R&D project proposals 
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Loop analysis: 
1. Loop - Willingness to give biobank consents (B): 
a. Describes how the number of biobank consents will saturate as the number of 
biobank consents increase, i.e. as the number of potential biobank donors 
decrease when consents are given and thus the likelihood of finding new 
biobank donors decreases. The availability of donor services (e.g. generic 
biobank information for citizens or online services for consent management 
and return of information) in a sense counterbalances the effect of this loop to 
some extend as long as the donor services are developed. The donor 
services block describes the likelihood for potential donors to be exposed to 
situations for giving consent and to eventually give their consent.  
2. Biobank revenue: 
a. Loop - Biobank revenue from R&D (R) 
i. The revenue from R&D projects enables biobanks to collect, store and 
analyse more samples and thus there will be more data available for 
the future R&D projects, which increases the number of R&D projects. 
b. Loop - Biobank revenue from research (R) 
i. Same as the Biobank revenue from R&D loop but for academic 
research sector. The revenue from research projects enables biobanks 
to collect, store and analyse more samples and thus there will be more 
data available for the future research projects, which increases the 
number of research projects. However, the fees collected by the 
biobanks are much smaller compared to the fees collected from the 
pharmaceutical companies. Thus the overall effect of academic 
research projects is expected to be smaller.  
3. Data enrichment: 
a. Loop - Enriching data R&D (R) 
i. When samples are analysed in R&D projects according to the biobank 
sample and data utilization contracts, the enriched data has to be 
returned back to the biobanks. This in turn increases the amount of 
available data resources for further use and therefore increases the 
likelihood of future projects. 
ii. We have assumed that the pharmaceutical companies enrich data to 
some extent, but at the same time this increases the costs of the R&D 
projects and thus also affects how many projects can be funded. 
b. Loop - Enriching data research (R) 
i. Same loop as the Enriching data R&D loop but for the academic 
research sector. When samples are analysed according to the biobank 
sample and data utilization contracts, the enriched data has to be 
returned back to the biobanks. This in turn increases the amount of 
available data resources for further use and therefore increases the 
likelihood of future projects. 
4. Findata: There are three different loops operating through Findata, i.e. Waiting time 
for accessing data, Resource intensity of data collection, and Data integration. These 
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three mechanisms all have an effect on the number of project starts and they are all 
driven by Findata's service fees, and therefore by the number of R&D projects. That 
is, the more Findata collects service fees, the more it has funds to develop its 
services. Thus, service fees have an important role, although, the development of 
Findata is mainly funded by public investments. 
a. Loop - Waiting time for accessing data (R) 
i. Describes the delay how long it takes for Findata to process the data 
applications and provide data permits. Findata develops the 
application process to reduce the evaluation time needed and to 
streamline the process.  
ii. We have assumed that the application processing delay has an effect 
on how interested the pharmaceutical companies are to initiate 
projects based on data. 
 
b. Loop - Resource intensity of data collection (R) 
i. Describes the effort in person-months needed by the applicant to meet 
all the requirements demanded by the data application process. 
Findata develops the application process to reduce the amount of 
duplicated work needed and to streamline the process.  
ii. We have assumed that the labor intensity has an effect on how 
interested the pharmaceutical companies are to utilize the data. 
 
c. Loop - Data integration (R) 
Describes the possibilities and efficiency of integration of different data 
sources. The ability to integrate data from different sources, namely 
from different national registers, healthcare service providers' registers 
and from biobanks, enhances the utility of the data. Data integration 
capability has therefore effect on the amount of available data 
resources for secondary use. The amount of data for secondary use 
affects in turn how interested the pharmaceutical companies are to 
utilize the data. Findata develops the integration capability of the 
different data sources. 
5. Academic publications: 
a. Loop - New academic publications from research (R) 
i. Describes the effect of publications resulting from academic research 
on R&D project ideas. Publications may lead to new R&D projects and 
thereby more service fees and returned data to biobanks and back to 
academic research. Biobank revenue from R&D and the loops 
containing Findata, i.e. Waiting time for accessing data, Resource 
intensity of data collection, and Data integration. 
b. Loop - New academic publications from R&D (R) 
i. Describes the effect of publication from pharmaceutical R&D projects 
on project ideas. The project ideas affect the number of R&D projects 
and as ending R&D projects publish a certain amount of academic 
publications on average, then the ending projects feed back to the 
academic publications.  The amount of academic publications of an 
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R&D project is expected to be lower compared an academic research 
project. 
6. The role of competence centers: 
a. Loop - Refinement of academic research (R) 
i. Describes the effect of competence centers (centers of excellence) on 
academic research. It is assumed in this model that the establishment 
of competence centers lead to better coordinated research and 
increase of quality and volume of academic publications. This loop 
enhances directly the Loop - New academic publications from research  
b. Loop - Refined research creates new ideas (R) 
i. Describes the effect of competence centers on R&D projects. 
Otherwise works the same way as the Loop - Refinement of academic 
research. 
7. Loop - Budget growth (R) 
a. Describes the growth of the R&D budget of pharmaceutical companies. This 
loop is one of the most important loops when considering the long term growth 
of the pharmaceutical companies' R&D expenditures, as the R&D budget is at 
some point in time going to saturate the growth of the number of R&D projects 
if it does not grow. The model assumes that the number of R&D project ideas 
affects the growth rate of R&D budget, i.e. if there is enough research ideas, 
then the budget is increased annually, thus causing an exponential growth 
defined by the annual growth rate. 
8. Support service: 
a. Loop - Support service lags behind (B) 
i. Describes how the demand and supply of support services affects the 
project proposals. As the number of R&D projects is growing relatively 
fast, it is likely that the supply of services lags behind the demand, 
depending on the growth strategies (i.e. the Loop - Free markets 
balance demand and supply) of the companies comprising the support 
services. If the support services cannot meet the demands of the 
ongoing R&D projects, then it is likely that this affects the future project 
proposals, as the pharmaceutical companies have difficulties in 
accessing the services needed for successful projects. Public 
investment can be used to enhance the growth of the support services 
to level off the discrepancy of the demanded and offered services. 
b. Loop - Free markets balance supply and demand (B) 
i. Describes how the supply and demand is balanced, i.e. how the 
support services react to the growing number of R&D projects. The 
faster this loop operates, that is, the smaller the delay for service 
development is, the faster the service offering of the support service 
matches the demand and the less problems this loop causes. Public 
investment can be used to enhance the growth of the support services 
and thus balance the supply and demand. This loop, if working slowly, 
can cause the supply to lag far behind the demand, and thus, affect 
the loop Support service lags behind cause to hinder the growth of the 
pharmaceutical R&D. 
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c. Loop - Support service growth (R) 
i. Describes the growth of the support services in the long term. As the 
number of R&D projects increase, the support services try to match 
this growth by the Loop - Free markets balance supply and demand. 
6.4 Simulations 
Simulation results of the number of R&D project starts is shown in Figure 12. The main 
parameter values are presented in Table 3. Table 4 contains an explanation for the scenarios 
presented.  
 
In Figure 12 the preliminary simulation results are presented. As can be seen, the different 
scenarios show a huge variability in the number of pharmaceutical R&D project starts, from 
50 to 150 projects per year. Our aim is to study what combination of public investment would 
be the most suitable strategy for the development of this business ecosystem. In here “most 
suitable” does not only mean optimal in terms of what amount of invested euros produces the 
highest amount of X (e.g. R&D project starts) in the system, but also the robustness of the 
scenarios under uncertainty. Currently, we haven’t been able to specify the exact parameter 
values of all the parameters or the exact formulation of cause and effect relationships, and 
therefore there is certain amount of uncertainty regarding these. More background 
information is being collected in order to improve the model and its input parameters.  
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Table 3: Main parameter values 
Parameters Value Units 
Biobanks and data     
Biobank unit price per project 0,05 MEuro/Project 
Units of samples per person 3 Sample/Person 
Sample accumulation per person 0,2 Sample/(Person*Year) 
Units of data per analysed sample 5 Data/Sample 
Average number of persons in a biobank project 5000 Person 
Unit price of sample collection 5 Euro/Sample 
Unit price of sample analysation 30 Euro/Sample 
Unit price of data for storage and administration 0,5 Euro/Sample/Year 
Share of analysed samples removed 0,5 Dmnl 
max data growth rate 0 1/Year 
Ref share of projects that need enriching 0,25 Dmnl 
R&D projects (pharmaceutical companies)     
R&D project planning delay 1 Year 
Ref R&D expenditures per project 1 MEuro/Project 
Ref annual growth rate of R&D budget 0,03 1/Year 
R&D budget growth starting year 0 Year 
Share of total R&D budget to data projects 0,5 Dmnl 
r&d project duration 2 Year 
Time for R&D to perceive available data 0,2 Year 
Time for R&D to perceive benefits of publications 1 Year 
Time for R&D to perceive benefits of competence centers 1 Year 
Time for R&D to perceive support service availability 1 Year 
ref biobank service cost 0,05 MEuro/Project 
Service operator (Findata)     
Service operator unit price per project 0,015 MEuro/Project 
Service operator development start time 0 Year 
Init labor intensity 0,8 Year/Project 
Init evaluation delay 1 Year 
Init data integration capability 0,5 Dmnl 
min labor intensity 0,1 Year/Project 
min evaluation delay 0,2 Year 
Research (universities and research institutions)     
Ref potential number of research project starts per year 50 Project/Year 
Average expenditure of research project 1 MEuro/Project 
Avg duration of academic research project 2 Year 
Support service     
Adjustment time of support service development 2 Year 
support service unit price per project 0,025 MEuro/Project/Year 
Publications     
Delay for academic publishing 1 Year 
publications per R&D project 0,5 Publication/Project 
publications per research project 2 Publication/Project 
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Table 4: Simulation scenarios 
Scenario name Scenario description 
Base Business as usual: BaU* 
S00 No investments 
S01 BaU + low investment in biobanks 
S02 BaU + extra investments in biobanks 
S03 BaU + no investments in Findata 
S04 BaU + extra investments in Findata 
S05 BaU + S02 + S04 
S06 S05 + extra investments in support services 
S07 S06 + investments in academic research + competence centers + genome center 
S08 S07 + low investments in biobanks 
S09 BaU + moderate consent cancellation rate 
S10 S07 + moderate consent cancellation rate 
  *Business as usual scenario: 
  Moderate investments in biobanks 
  Moderate investments in Findata 
  Low investments in support services 
  Low investments in competence centers 
  Low investments in genome centre 
  Low investments in academic research 
  No consent cancellations 
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Figure 12: Preliminary simulation results.  
It is difficult to estimate the effect of some of the interconnections described in the model as 
there is no data available in some of the cases. For example, what is the effect of the 
variable Labor intensity of accessing data on R&D project proposals? At the moment, we 
have estimated the effect as well as possible, and as the project continues, we are going 
improve the estimation based on comments from PreMed project participants and external 
experts. Also, we have conducted extensive sensitivity analyses to study the effects of 
different interconnections in the model and to identify the key variables and feedback loops in 
the system. As, even though all feedback loops have an effect on the system, some are 
significantly more important when considering the future development of the ecosystem. 
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6.5 Results 
Preliminary analysis of the model suggests that public investments in biobank operations 
(e.g. for sample analysation) are very important at this point of the development of the 
ecosystem. As the revenue stream from data utilization service fees is not nearly enough to 
cover the expenses of the biobanks. Also, in order for the ecosystem to be healthy in the 
long run, the biobanks have to find different ways of monetarizing the samples and data they 
base their business.  
The results given in Figure 12 are only preliminary and we continue to specify the parameter 
values used as well as to improve the model structure. The model and parameter settings 
will be adjusted during the third phase of the project.  Updated results along with analysis 
and discussion are expected during first half of the year 2020.  
7. Follow-up of the PreMed project domain 
7.1 Dissemination and networking activities  
During its second phase the project has organised three workshops where topical 
presentations related to secondary use of data have been given and the progress of the 
PreMed project has been reported. In addition to project participants, also external experts 
have been participated as invited guests. Other dissemination and networking activities 
include: (1) two poster presentations in scientific conferences (NBCC 2019, EMBC 2019), (2) 
other conference presentations (HIMSS, DHN, ECHA, Smart Health for Europe), (3) FinnGen 
and Health Tuesday events, (4) continuously updated  project website, (5) news release 
(12.3.2019) giving rise to two network magazine articles and (6) VTT blog (21.3.2019).  
Additionally, several presentations on PreMed have been given in the context of visits of 
international groups in Finland (Korea, China/Sichuan, Singapore).  
7.2 Roadmap  
The PreMed project has provided a compact roadmap table highlighting important 
developments towards the data-driven precision medicine ecosystem and related 
infrastructures (Table 5). The national infrastructure for secondary use of data took a step 
forward in May 2019 as the act on secondary use of health and social services data came 
into effect. Consequently, the new data permit authority (Findata) was established, with first 
services gradually starting during year 2020.  Another important step towards centralised 
services was the opening of the Fingenious service of the Finnish Biobank (FinBB). 
Fingenious enables feasibility and access requests to be done for all hospital biobanks and 
the THL biobank via one joint service. The relation between Findata and FinBB remains still 
unclear, but it is expected that a "one-stop shop" covering also services to link biobank data 
and samples with national registry data is targeted and could be available by 2022. Based on 
information from Findata web site, the Findata services will gradually start during 2020 and 
will be extended to Kanta services by 2021. Progress of the national centers of excellence 
has been slower than expected. However, it seems that the remaining three planned centers 
(neuro, pharma development and genome) could finally be established in year 2020. 
Development of additional centers covering other areas of healthcare might start in 2021.  
The enforcement of the genome law will be followed by the development of the genome 
database. We expect the first version of the genome database to be in operation in 2022 in 
the most positive case. The genome center web page does not provide any estimate on the 
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time schedule1. The on-going FinnGen project has exceeded expectations in collecting 
sample donors. It is expected that the project is able to achieve the targeted amount (500 
000) of genotyped participants by 2023 as planned. The project attracted two new pharma 
company partners (GSK and Sanofi) in 2019. Negotiation with additional partners is on-going 
and are expected to be published in 2020. Open API interfaces provided by new EHR 
systems will improve the possibilities to integrate AI-based and data-driven tools with 
healthcare processes. The usage of the new Apotti system will considerably increase after 
the second deployment in May 2020.  
Kanta services are the core of the national infrastructure enabling access to health data and 
since year 2019 also for social data. The MyKanta (OmaKanta) services will include social 
services data in the beginning of 2020. Prominent enhancements of the Kanta system also 
include the introduction of the Kanta PHR service ("Omatietovaranto") which enables health 
and wellness applications to be connected via an open API interface. Value of the service is 
expected to increase later (expected 2022), when data can be exchanged between health or 
social care organization and the citizen via the PHR. Currently, the PHR does not enable 
such data sharing. The Kanta PHR enables the citizens to manage and share their health 
data. Thereby, it is a potential solution for sharing personal data also for secondary use.  
The reform of the Finnish social and health services system has been delayed, but the 
expectation is that the work proceeds and leads into improved service delivery system.  
Efficient exploitation of data (e.g. in management and value-based healthcare) is expected to 
be an important element of the new service system.     
New EU regulation  - clinical trial regulation (CTR) and medical device regulation (MDR)  - 
will be enforced in 2020. The new CTR brings a major change to the way clinical trials are 
conducted in the EU. In particular, it will harmonize practices and improve collaboration 
among the member states. The new MDR will significantly expand the definition of medical 
devices. In particular, software used for a medical purpose (e.g. a decision support system) 
will fall under class IIa or higher and require certification by a notified body. The new in-vitro 
diagnostics regulation (IVDR) will be enforced in 2022.  
As indicated in Table 6 the services for biobank donors are still scarce. However, in line with 
the GDPR, register controllers would need to provide information for donors concerning the 
use of biobank samples and patient data. Consequently, there is currently strong interest 
towards setting up services for biobank donors, and we believe that new services will 
gradually become available in 2021. 
As precision medicine projects are consuming substantial public investments, they are 
expected to provide direct benefits in healthcare. We expect direct impacts to be seen e.g. 
through the adoption of pharmacogenomics and polygenic risk scores in healthcare.    
Finland will host the HIMSS Europe and Health 2.0 international conference during years 
2019, 2020 and 2021.  Already the first conference of the series was a success and enabled 
Finland to promote its capabilities and infrastructures for data-driven precision medicine. The 
events of 2020 and 2021 provide an opportunity to attract further interest towards Finland.   
The PreMed project ends in the end of 2020. The PreMed PGx study is expected to provide 
a useful model for new industry-driven biobank projects and valuable experience for 
biobanks, national registries, FinBB and Findata  to improve data access processes. During 
year 2020 a follow-on project will be prepared with the objective to start PreMed 2.0 in 2021. 
Concrete impact, e.g. new business opportunities and products based on data are expected 
                                               
1 http://www.genomikeskus.fi/en/q-a.html 
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in year 2022.  A permanent organisation to coordinate data-driven precision medicine 
ecosystem may turn out to be needed and could be established in 2023.   
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Table 5. Data-driven precision medicine roadmap 
 
 
2019 2020 2021 2022 2023  
Biobanks • FinBB / Fingenious: joint 
feasibility and access requests 
[3] [12]  
• Biobank Act renewal in force 
 
• one-stop shop for joint biobank 
studies 
 
Secondary use of 
data 
• Legislation on Secondary use of 
social and health data in force 
[4] 
• FinData services start gradually 
[2] 
• Findata response times comply 
with secondary use legislation 
and apply also to Kanta [4] 
 
• services cover hospital data 
lakes and all Kanta data  [1]  
National centers of 
excellence 
(genome, cancer, 
neuro, pharma 
development) 
• draft genome law released for 
comments [8] 
• establishment of the national 
cancer center [6] 
• establishment of other national 
centers of excellence  [5][7][8]: 
neuro, pharma development, 
cancer, genome 
• genome law [13] 
• preparation of additional national 
centers starts  
• first version of genome database 
in operation 
• genome database integrated 
with patient information systems 
Projects • FinnGen data available: 180k 
[10],  new partners join 
• Apotti in limited use 
• FinnGen data available for 250k 
individuals,  new partners join, 
second phase starts 
• Apotti 2nd deployment phase [9] 
• FinnGen data available: 320k 
• business arising from FinnGen 
(in Finland): 15 M€ [11] 
• BF: PH and AI programs 
completed 
• FinnGen data available: 390k • FinnGen data available: 500k 
• business arising from FinnGen 
(in Finland): 48 M€ [11] 
Finnish healthcare 
system  
• centralized service for social 
data in use (Kansa) 
•  
• more connected Kanta PHR 
apps (in addition to Terveyskylä)  
[14] 
• social data in MyKanta 
 
• healthcare professionals’ access 
to  personal data in Kanta PHR 
• Kanta data in secondary use 
• Clinical data accessible in Kanta 
PHR 
•  SOTE reform in force    
International 
 
• large number of precision 
medicine initiatives ongoing 
• cross-border ePrescription with 
Estonia   
• Finnish EU presidency 
• HIMSS Europe and Health 2.0 
2019 in Finland 
• EU clinical trial regulation 
enforced [15] 
• EU medical device regulation 
(MDR) enforced [16] 
• UK Brexit  
• HIMSS Europe and Health 2.0 
2020 in Finland 
• Donor’s access services of 
biobanks becoming increasingly 
available as a consequence of 
legislation 
• HIMSS Europe and Health 2.0 
2021 in Finland 
• Impact of precision medicine in 
healthcare (pharmacogenomics,  
polygenic risk scores, etc.) 
• EU in vitro diagnostics regulation 
(IVDR) enforced [16] 
•  
Business 
ecosystem 
• PreMed: biobank study 
execution and ecosystem 
simulation tool development   
• discussion on parallel 
collaboration projects  
• PreMed: system dynamics 
model for data exploitation  
• recommendations for public 
bodies to boost growth 
• preparation of follow-on project 
(PreMed 2.0) 
• start of  PreMed 2.0 targeting at 
building international co-
operation and business 
opportunities (content and target 
country to be defined)  
• PreMed 2.0 continued. Project 
impact in opening business 
opportunities for data-driven 
products and services 
• PreMed 2.0: establish 
permanent organisation for data-
driven ecosystem coordination 
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7.3 International developments  
In phase 1 of the PreMed project a review of international activities in precision medicine was 
carried out1. During phase 2 we have followed up some of the ongoing major international 
initiatives. Table 6 shows examples of major initiatives with information about study 
approach, clinical focus, number of participants, and funding. The table also summarizes the 
policies of the initiatives concerning access to data and/or samples by researchers, industry 
and the donors themselves.  
The initiatives are based on different strategies in enrolling participants. Some of the 
initiatives (e.g. All of Us and UK Biobank) try to attract a wide variety of citizens as 
participants and a substantial proportion of their participants are healthy volunteers. 
Following up such populations enables risk factors of diseases of common diseases to be 
detected and evaluated. Other initiatives (such as FinnGen and 100k genomes project) 
recruit most or all of the participants in healthcare settings. These cohorts are dominated by 
individuals with existing health conditions. Thereby, the collected data and sample resources 
are highly valuable in detailed studies on individual diseases (including rare diseases) and 
related therapies. National Human Genome Research Institute (NHGRI) and Australian 
Genomics are examples of programmes enabling collaboration and funding of research, 
forming a basis for a wide range of individual research projects. In terms of absolute number 
of participants the All of Us project is highest with targeted cohort of one million individuals. 
FinnGen with the targeted 500000 participants is comparable to corresponding initiatives of 
UK and China. When measured by participants per population or by invested funding per 
population Estonian biobank and FinnGen are unique in size. 
Concerning the objectives of the PreMed project, it is of interest to observe how the data and 
sample collections gathered in the initiatives are available for use for the different  
stakeholder groups: external researchers, companies and donors. Most of the initiatives 
enable access to data and/or samples for external researchers by default. The access is 
always subject to a research plan with valid scientific objectives. There is more variability in 
the policies of granting access for companies. Most of the initiatives (e.g. FinnGen, UK 
Biobank, 100k Genomes Project and All Of Us) enable the use of data and samples by 
companies as long as the use is based on a valid research plan with scientific objectives. 
 The FinnGen the project group includes researchers from both universities and pharma 
companies. After the project, the genome data is returned to Finnish biobanks, where it is 
available for scientific research (including research carried out by companies). Some of the 
initiatives (e.g. Estonian Biobank and the EPIC study) have not explicitly communicated at 
their web pages their policy towards industry driven studies. Kadoorie biobank limits the 
access to public research organizations and health service organisations. None of the 
initiatives listed Table 6 disclose data for industrial R&D without a valid research plan with 
scientific research setting and objectives.  
Accessing own data is increasingly seen as a fundamental right of the donor and also an 
important opportunity for the biobanks and research projects to attract volunteers to 
participate. As seen in Table 6, not much have been done yet to enable the donors to access 
data retrieved from their samples (e.g. genomic variants) or even to access general 
information about the studies where their data or samples have been used. The All of Us 
project has recently announced a genetic counselling service, which would enable to share 
                                               
1 PreMed Phase 1 report: 
https://cris.vtt.fi/ws/portalfiles/portal/20131333/PreMed_ecosystem_stakeholder_needs_and_opportuni
ties.pdf 
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genotyping and sequencing results with the donors along with appropriate counselling1. The 
Estonian Biobank has started providing data for the donors. So far, 2000 donors (1% of total 
participants) have received their polygenic risk score (PRS) along with counselling2. Helsinki 
Biobank has carried out a study concerning the return of results to the donors3. The study 
provides a proposal for a joint donor portal for the Finnish biobanks4.  
The 100k Genomes Project provides clear guidance for the participants concerning return of 
findings5. Findings related to the original disease (participant's reason to participate) are 
always returned to the participant. The participant needs to accept this in order to be 
included in the study. Additionally, the participant may choose to allow "additional findings" to 
be looked for and returned - e.g. genomic variants. Any findings will be first fed back to the 
NHS, to confirm the result. A clinician then gives the results to the participant along with 
discussion on their meaning. The 100k Genomes Project web page does not provide 
information on how extensively findings have been returned in practice. 
                                               
1 https://allofus.nih.gov/news-events-and-media/announcements/nih-funds-genetic-counseling-
resource-ahead-million-person-sequencing-effort 
2 https://www.slideshare.net/THLfi/andres-metspalu-the-estonian-genome-project 
3 https://www.finngen.fi/sites/default/files/inline-files/Return%20of%20results_250419.pdf 
4 https://www.vtt.fi/sites/premed/Documents/Vaatimusmaarittely%20osallistamisportaalille.pdf 
5 https://www.genomicsengland.co.uk/information-for-participants/findings/ 
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Table 6. Examples 
of precision 
medicine initiatives. 
 Initiative Approach Clinical focus 
N / share of 
population   
(thousands /  
%) 
Yearly 
funding 
total (M€) 
Yearly funding 
per population 
(€) 
Access to 
external 
researchers 
Access to  
industry Donor’s services 
All of Us  / NIH  (USA) 
[18] 
prospective cohort all diseases 1000 / 0.30% 258
1
 0,8 yes yes 
Genetic counselling service being 
developed 
UK Biobank [19] prospective cohort all diseases 500 / 0.75% 152 0,2 yes yes n/a 
China Kadoorie biobank 
(China / UK) [20] 
prospective cohort chronic diseases 500 / 0.04% n/a n/a yes 
no (only HC 
organizations) 
n/a 
Estonian Biobank [17] prospective cohort all diseases 200 / 15% 2,33 1,7 yes 
yes  
(not ruled out) 
Yes, partial  
(PRS + counselling) 
EPIC study / IARC-
WHO [21]  
prospective cohort chronic diseases 520 / 0.14% n/a n/a yes 
yes  
(not ruled out) 
n/a 
100k Genomes Project 
(UK) [23] 
research project 
rare diseases, 
cancer 
85 / 0.13% 454 0,7 yes yes 
Results return process defined and 
documented (no online service) 
FinnGen  (Finland) [24]  research project all diseases 500 / 9.1% 105 1,8 yes yes 
Right to get information on findings 
(no online service) 
NHGRI / NIH (USA) [25] 
research/collaboration/ 
funding programme 
genetic diseases, 
cancer 
n/a 3256 1,0 yes 
depending on 
project 
n/a 
Australian Genomics 
[26] 
research/collaboration/ 
funding programme 
rare diseases, 
cancer 
n/a 187 0,73 n/a n/a Online service for consent giving 
                                               
1 US congress approval for year 2018: https://allofus.nih.gov/news-events-media/media-toolkit/all-us-research-program-backgrounder 
2 MRC and Wellcome Trust funding: https://www.ukbiobank.ac.uk/wp-content/uploads/2018/10/Funding-UK-Biobank-summary.pdf 
3 Based on year 2019 investment:  https://www.sm.ee/en/news/genome-project-100000-samples-collected-2019-least-50000-more-people-can-join 
4 Based on public funding decision for 2015-2020:  https://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/funding-for-genomics-england-to-reduce-by-40m-under-2019/2020-dhsc-
spending-plans/20206548.article?firstPass=false 
5 Based on budgeted funding of 59 M€ for 2017 - 2022: https://www.finngen.fi/en/node/38 
6US government funding budgeted for 2019, https://www.genome.gov/Pages/About/Budget/NHGRIFY2019CJ.pdf 
7 Based on announced funding round, https://www.australiangenomics.org.au/grants-round-opens-for-65-million-genomics-research-fund/ 
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8. Conclusions 
PreMed project activities carried out in the phase 2 (1.11.2018 - 31.12.2019) have been 
reported. The activities have been focused in three main areas: biobank study (research 
protocol, data collection, data analysis environment setup), ecosystem simulation model  and 
dissemination (project workshops and other events).  
The biobank study carried out in the PreMed project aims to provide evidence on the benefits 
of genome-based tests in the context of drug therapy. In this way, it is expected to promote 
the use of genome tests and related services in healthcare.  At more general level, PreMed 
provides information and experiences of the processes related to healthcare data access.  
Thereby, it is expected to lower the threshold for companies to exploit healthcare data and 
results from retrospective studies in their business. 
The biobank study lags behind the original time schedule by six months due to delays in the 
data collection process. The six months extension from original project ending (30.6.2020) 
has been accepted by the project partners and Business Finland.  Despite of the delay, the 
objectives of the study have not been changed. All needed data resources seem to be 
accessible and all needed administrative decisions concerning data disclosure have been 
made.  
The project has already been of benefit in pointing out bottlenecks in accessing data 
resources especially related to combining data from different registers. These experiences 
are expected to be valuable in the further development of services for data access, in 
particular those of Findata and FinBB.   
The data-driven precision medicine ecosystem model and its implementation as a simulator 
was carried out in two parts. The first version with limited functionality was developed and 
completed by July 2019. Subsequently, the simulator was enhanced by adding several new 
features during the rest of the year. The primary outcome measure of the simulator is the 
volume of real world data projects making use of data obtained from biobanks and national 
registers. The ecosystem model enables the simulation of various ecosystem evolution paths 
affected by different public investment strategies. The effect of investments to biobanks, 
Findata, academic research, national centers of excellence and support services provided by 
SME companies can be estimated. The model and its parameters are still under 
development. Initial results have been provided in the report. The simulator is expected to be 
valuable for public entities and authorities in providing support for the selection of financing 
strategies to boost ecosystem growth. Also other stakeholders can find the simulator useful 
in increasing the understanding of the ecosystem dynamics.         
During its second phase the project has organised three workshops where topical 
presentations related to secondary use of data have been given and the progress of the 
PreMed project has been reported. The Finnish health data resources are globally unique. 
They provide an excellent basis for world class products and services in the health and 
wellness domain.  One important objective of the project is to ensure that opportunities for 
companies to exploit data in compliance with GDPR will be taken into account. PreMed is in 
a good position to achieve this objective thanks to the strong participation of companies.    
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Terms and acronyms 
 
Term / acronym Description 
ADR adverse drug reaction 
AI artificial intelligence 
API application programming interface 
ATC Anatomical Therapeutic Chemical 
B2B  business-to-business 
B2C business-to-consumer 
BBMRI Biobanking and BioMolecular resources Research and 
Infrastructure 
CDSS clinical decision support system 
CSV comma separated file 
DDD Defined Daily Dose 
DHN Digital Health Nordic 
ECHA European Connected Health Alliance 
EHR electronic health record 
FDA Food and Drug Administration 
FINBB Finnish Biobank co-operative 
FTP file transfer protocol 
GDPR general data protection regulation  
HCRU healthcare resource use 
HIMSS Healthcare Information and Management Systems 
Society 
HUS The Hospital District of Helsinki and Uusimaa 
ICT information and communications technology 
INR international normalized ratio 
ISTH International Society on Thrombosis and Haemostasis 
IVDR in-vitro diagnosis regulation 
Kela The Social Insurance Institution of Finland 
MDR medical device regulation 
MTA Material Transfer Agreement 
NBCC Nordic-Baltic Cardiology Conference 
NHGRI National Human Genome Research Institute 
NIH National Institute of Health 
PGx pharmacogenomics 
PHR personal health record 
PM precision medicine 
PRS polygenic risk score 
RTF rich text format 
SD system dynamics 
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SFTP secure file transfer protocol 
SMEs small and medium-sized enterprises 
STM Ministry of Social Affairs and Health 
THL National Institute for Health and Welfare  
TTR time in therapeutic range 
 
